MedElevator
Войти в исследования Clinical medicine insights. Case reports · 2026
Paraneoplastic Pemphigus Associated With Renal Cell Carcinoma. Rare Case Report and Literature Review.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ahmed Halkawt Babarasul, Karim Hawnaz Atta, Mohammed Othman Abdulrahman, Aziz Jeza Muhamad Abdul, Salih Mohammed Kaka Bra, Bhandari Parshal
Аннотация
INTRODUCTION: Paraneoplastic pemphigus (PNP) is an uncommon autoimmune blistering disorder frequently associated with underlying malignancies. Renal cell carcinoma (RCC) is the most common primary renal cancer. It is associated with a wide range of paraneoplastic syndromes, but occasionally presents as a dermatological finding.
CASE PRESENTATION: A 56-year-old woman with severe oral and cutaneous lesions was diagnosed with PNP associated with renal cell carcinoma (RCC). The patient was treated with 1 g of rituximab as an infusion, and after two weeks, another dose of 1 g of rituximab was administered in combination with steroids (prednisolone 0.5 mg/kg) until control, then gradually decreasing by 25% each month, until we reached 5 mg/day. The patient achieved complete clinical remission at 6 months; however, long-term outcomes remain unknown because she was subsequently lost to follow-up.
CONCLUSION: A comprehensive workup is crucial for diagnosing the underlying tumor associated with this phenomenon. Rituximab- and steroid-based therapies may be effective in controlling PNP symptoms.
CASE PRESENTATION: A 56-year-old woman with severe oral and cutaneous lesions was diagnosed with PNP associated with renal cell carcinoma (RCC). The patient was treated with 1 g of rituximab as an infusion, and after two weeks, another dose of 1 g of rituximab was administered in combination with steroids (prednisolone 0.5 mg/kg) until control, then gradually decreasing by 25% each month, until we reached 5 mg/day. The patient achieved complete clinical remission at 6 months; however, long-term outcomes remain unknown because she was subsequently lost to follow-up.
CONCLUSION: A comprehensive workup is crucial for diagnosing the underlying tumor associated with this phenomenon. Rituximab- and steroid-based therapies may be effective in controlling PNP symptoms.